IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$40.59+2.14 (+5.57%)
Close on Nov 18, 2026Market cap $41.28MP/E –Yield –
IRulya Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
IRulya Therapeutics's price to book ratio was 20.6× on Jul 31, 2026, against 42.3× a year earlier. Over the last 5 years it ranged from 4.4× to 402.0×, with a median of 18.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 20.6× | −130.2 |
| 2025 | Oct 31, 2025 | 150.8× | +114.8 |
| 2024 | Dec 31, 2024 | 36.0× | +26.8 |
| 2023 | Dec 29, 2023 | 9.2× | +4.8 |
| 2022 | Dec 30, 2022 | 4.4× | −52.4 |
| 2021 | Dec 31, 2021 | 56.8× | −30.3 |
| 2020 | Dec 31, 2020 | 87.2× | −149.6 |
| 2019 | Dec 31, 2019 | 236.8× | – |
See a number that looks wrong?